Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Frequently asked questions
What sector does ANEBULO PHARMAC. DL-001 (214) operate in?
ANEBULO PHARMAC. DL-001 belongs to the Healthcare sector and operates in the Biotechnology industry.
What is ANEBULO PHARMAC. DL-001 (214) current stock price?
As of the latest data, ANEBULO PHARMAC. DL-001 stock price is €0.75, with a previous close of €0.75.
What is ANEBULO PHARMAC. DL-001 (214) current market capitalization?
ANEBULO PHARMAC. DL-001 market cap is approximately 30.38 million.
What is ANEBULO PHARMAC. DL-001 (214) Earnings Per Share (EPS)?
The trailing EPS is -€0.15.
Does ANEBULO PHARMAC. DL-001 (214) pay dividends?
No. ANEBULO PHARMAC. DL-001 does not pay a dividend.
What is ANEBULO PHARMAC. DL-001 (214) beta (volatility) score?
ANEBULO PHARMAC. DL-001 has a beta of -1.615, indicating lower volatility than the overall market.